New radiation drug targets Hard-to-Treat cancers in early trial
NCT ID NCT07595237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug (177Lu-DOTA-SNA040) that delivers radiation directly to cancer cells with a specific marker (Claudin 18.2). It is for people with advanced stomach, pancreatic, or bile duct cancers that have worsened after standard treatment. The main goals are to check safety, find the right dose, and see if the drug reaches tumors. Only 12 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS (SUCH AS ADENOCARCINOMA AT THE GASTROESOPHAGEAL JUNCTION) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200000, China